Wird geladen...
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer
At the 2010 meeting of the European Society for Medical Oncology (ESMO), a landmark development in prostate cancer therapy was unveiled. In a phase III study, the CYP17 inhibitor abiraterone yielded a survival advantage over placebo in patients with metastatic castration-resistant prostate cancer (m...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3161066/ https://ncbi.nlm.nih.gov/pubmed/21093995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.maturitas.2010.10.009 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|